Joel Greenblatt Adma Biologics, Inc. Transaction History

Gotham Asset Management, LLC

$21.9 Billion
Q3 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 11,011 shares of ADMA stock, worth $171,331. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,011

Previous 108,993 89.9%

Holding current value

$171,331

Previous $1.98 Million 91.89%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$14.66 - $19.91 $1.44 Million - $1.95 Million	-97,982 Reduced 89.9%	11,011 $161,000
Q2 2025 Aug 14, 2025	SELL	$17.6 - $24.51 $972,470 - $1.35 Million	-55,254 Reduced 33.64%	108,993 $1.98 Million
Q1 2025 May 15, 2025	SELL	$15.44 - $20.61 $37,781 - $50,432	-2,447 Reduced 1.47%	164,247 $3.26 Million
Q4 2024 Feb 14, 2025	BUY	$15.62 - $22.62 $33,254 - $48,157	2,129 Added 1.29%	166,694 $2.86 Million
Q3 2024 Nov 14, 2024	BUY	$11.21 - $20.03 $968,734 - $1.73 Million	86,417 Added 110.58%	164,565 $3.29 Million

Q2 2024 Aug 14, 2024	SELL	$5.98 - $11.18 $103,645 - $193,771	-17,332 Reduced 18.15%	78,148 $873,000
Q1 2024 May 15, 2024	BUY	$4.4 - $6.74 $113,920 - $174,505	25,891 Added 37.21%	95,480 $630,000
Q4 2023 Feb 14, 2024	SELL	$3.08 - $4.52 $18,572 - $27,255	-6,030 Reduced 7.97%	69,589 $314,000
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $50,537 - $67,140	14,564 Added 23.85%	75,619 $270,000
Q2 2023 Aug 14, 2023	BUY	$3.12 - $4.22 $92,139 - $124,625	29,532 Added 93.68%	61,055 $225,000
Q1 2023 May 15, 2023	SELL	$3.01 - $3.87 $33,070 - $42,519	-10,987 Reduced 25.85%	31,523 $104,000
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $104,999 - $164,938	42,510 New	42,510 $164,000

Others Institutions Holding ADMA

# of Institutions

401

Shares Held

205M

Call Options Held

3.06M

Put Options Held

1.88M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.06B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account